Clinical trial
Plasma-Adapted First-Line Pembro In NSCLC
NCT04166487
Study timeline
Study start (actual)2020-01-13Date precision: day
Registry last updated2026-07-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
NSCLC Stage IVunresolved
Metastatic Non-Small Cell Lung Cancerunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
PEMETREXEDDRUG · verified · RxNorm: pemetrexed
CARBOPLATINDRUG · verified · RxNorm: carboplatin
PACLITAXELDRUG · verified · RxNorm: paclitaxel
InVisionDIAGNOSTIC_TEST
Sponsors & collaborators
Julia K. Rotow, MDlead sponsor
Inivatacollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04166487 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.